A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
Latest Information Update: 12 May 2022
At a glance
- Drugs TBX-2400 (Primary)
- Indications Acute myeloid leukaemia; Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiga Biotechnologies
- 01 May 2022 Planned initiation date changed from 1 Feb 2022 to 1 Sep 2022.
- 11 Jan 2022 Planned initiation date changed from 1 Dec 2021 to 1 Feb 2022.
- 10 Nov 2021 Status changed from not yet recruiting to recruiting, according to a Taiga Biotechnologies media release.